Sales of the multiple myeloma drug Darzalex (daratumumab) have hit $2.5 billion in a calendar year, which is good news not just for Janssen, the exclusive global license holder.
The milestone is also a happy one for the Danish biotech company Genmab (Nasdaq: GMAB), which discovered and out-licensed the therapy to the Johnson & Johnson (NYSE: JNJ) unit.
Genmab will receive $100 million from Janssen because this milestone has been met, and next year could be an even better one for sales of the drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze